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Abstract: Peer review is an essential component of the process that is universally applied 
prior to the acceptance of a manuscript, grant or other scholarly work. Most of us willingly 
accept the responsibilities that come with being a reviewer but how comfortable are we with 
the process? Peer review is open to abuse but how should it be policed and can it be improved? 
A bad peer review process can inadvertently ruin an individual’s career, but are there penal-
ties for policing a reviewer who deliberately sabotages a manuscript or grant? Science has 
received an increasingly tainted name because of recent high proﬁle cases of alleged scientiﬁc 
misconduct. Once considered the results of work stress or a temporary mental health problem, 
scientiﬁc misconduct is increasingly being reported and proved to be a repeat offence. How 
should scientiﬁc misconduct be handled—is it a criminal offence and subject to national or 
international law? Similarly plagiarism is an ever-increasing concern whether at the level of 
the student or a university president. Are the existing laws tough enough? These issues, with 
appropriate examples, are dealt with in this review.
Keywords: peer review, journal impact factors, conﬂicts of interest, scientiﬁc misconduct, 
plagiarism
Dear Editor: Do you have a problem? 
“All that is necessary for the triumph of evil is that good men do nothing.” This 
common quote is attributed to Edmund Burke, born in Dublin in 1728, died in 
Beaconsﬁeld, Buckinghamshire (on 8 July) 1797. The use of this quotation is so 
common that it is rare that one even bothers to acknowledge Mr. Burke or the text 
from which this quote has been supposedly extracted—too bad because, no doubt, 
this would be, by today’s classiﬁcation, a citation classic. With web searching so 
easy it should be easy to locate the precise source of a quotation. Are we then guilty 
of plagiarism? Have the Editors of this journal failed in their task of due diligence 
in accepting this review article? Will our institutions be brought to task for this 
transgression? Should there be a national or international body to deal with such 
matters? In this article the brothers Triggle discuss these and other matters related to 
the integrity of science and offer their opinion as to the future of peer review. They 
bring over 85 years of academic experience, over 400 peer reviewed manuscripts 
(including a number jointly authored, including one book) and over 6000 citations 
for their collective works. Vascular Health and Risk Management 2007:3(1) 40
Triggle and Triggle
Why do we need peer review? 
Peer review should provide due diligence to a manuscript 
or grant and this requires a considerable time commit-
ment. This is not new: peer review has a long history, 
predating even the review process of the Philosophical 
Transactions of the Royal Society, initiated in 1752. For 
the first 100 years of the journal’s existence decisions 
on publication were the responsibility of the editor alone 
and those of his colleagues whom he might have asked 
(Eaton 1997; Spier 2002). With the very rapid expansion 
in both the numbers of journals as well as sub-specialities 
it is now, of course, unreasonable to expect any single 
editor to possess the vision and depth of knowledge to 
be competent in all areas. With many journal reviews 
now “on line” the peer review process is presumably 
more efficient, with the attendant potential cost of an 
increase in the number of requests that the efficient re-
viewer receives. Peer review is widely, and perhaps almost 
universally, regarded to be an essential component of the 
scientiﬁc review process and to provide quality control so 
that the published works meet appropriate standards. Most 
of us would agree, at least in public, that peer review works 
reasonably well, but it is certainly not without its problems 
and the issue is what could be better or constitute improve-
ments. An important ﬁrst question is to deﬁne “peer”? One 
deﬁnition (from The Concise Oxford Dictionary) is: “A 
person who is equal in ability, standing, rank or value.” Is 
it then ethical for a peer to pass a review on to a junior 
postdoctoral fellow? The junior fellow requires develop-
ing experience as a reviewer but should that be obtained 
by reviewing manuscripts/grants that were originally 
directed elsewhere? We all have personal views on the 
fairness of peer review. Winston Churchill’s comment 
on democracy comes to mind, “…democracy is the worst 
form of government except all the others that have been 
tried”. However, that being said, like everything else the 
peer review process should evolve—the question is: “In 
what direction and should the peer review process actu-
ally police scientific fraud and should the peer review 
itself be subjected to review and potential legal action if 
scientific fraud by the reviewer is suspected?” (see Ready 
2006). This topic is the focus of much recent discussion 
in both the scientific and public press (inter alia, Altman 
2006; Bosman 2006; Couzin and Unger 2006; McCook 
2006; Marris 2006). Nature Medicine, in its May 2005 
2006 issue, ran a series of commentaries titled “Focus On 
Fraud” that reflect the high level of concern that is being 
focused on matters of scientific integrity. 
“My gut feeling is that this will not 
work!” “Yes, but please justify that 
statement.” Does anonymity lead  
to laziness? 
The argument for reviewers remaining anonymous is that they are 
then protected from retribution from a potentially irate author(s). 
Furthermore, the pool of available reviewers may dramatically 
decline if the names of all reviewers were published. This all 
assumes, of course, that maximal effort and fair judgment is 
provided to every submitted manuscript and this, unfortunately, 
is not always the case. Not infrequently reviewers will include 
un-qualiﬁed statements such as, in an extreme case, “My gut 
feeling is that this is incorrect”, in their review that may, 
in fact, itself be a scientiﬁcally incorrect statement! Such 
useless statements then leave the journal editor, or grant 
panel chair, with the task of evaluating and rejecting the 
reviewer’s review. Worse, though is that such an incompe-
tent review may lead to the rejection of the submitted paper, 
or of the grant application, and the ultimate failure of the 
career of the author. Could this happen? Yes, indeed and 
we will discuss an example later when a Texan general 
practitioner decided to fight back after he argued that 
he was victimized by the peer review process. To their 
credit many agencies do make every effort to weed out 
the inaccurate review and, in fact, vigorously review 
and rate the reviews, rejecting some reviews, as well as 
developing preferred lists of reliable reviewers. Without 
doubt the review process could be greatly improved and the 
process fairer if reviewers substantiated their statements with 
appropriate references to peer reviewed articles that, in turn, 
provide positive feed back to the authors. In other words 
consider the review itself as a scholarly document. Just as a 
manuscript may be rejected, or a grant receives a low score, 
if the authors fail to demonstrate/indicate knowledge of the 
ﬁeld then should their review be rejected if it fails to meet 
minimal standards? 
So why not publish the reviews? 
If the review itself is to be a scholarly document then why not 
publish such reviews together with the suitably revised reviewed 
manuscript, perhaps just highlighting in the review the key 
controversial aspects and presenting the reviewed paper in the Vascular Health and Risk Management 2007:3(1) 41
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perspective of the published ﬁeld of knowledge? If the reviewer 
goes to the trouble of providing a critical review that discusses 
both the key ﬁndings as well as the limitations of the study then 
surely this warrants the equivalent of a “Letter to the Editor”. 
Letters to the editor are already a feature of many jour-
nals so why not extend such a process by including a sec-
tion dealing with “Highlights from Reviews of Published  
Manuscripts”—another section for your CV and your institution 
to evaluate during promotion and tenure considerations. A num-
ber of journals, including Nature and Science, do after all provide 
News and Views columns that could easily be extended. 
A strong case for publishing reviews, or criticisms, of 
a published paper has been made by Eaton (1997). Eaton 
(1997) focused on “position papers or statements” that 
were intended to inﬂuence medical practice, but, in some 
instances, such position papers may have inappropriately 
dismissed alternative approaches/views. To quote Eaton 
(1997): “Medical science can only ﬂourish in a free society 
and dies under totalitarian repression.” Of interest is that 
in the ﬁctional work ‘State of Fear’, by Michael Crichton 
(2004), the millionaire philanthropist, George Morton, also 
argues in favor of the publication of both the article and the 
peer reviews in the same issue as a means for “clearing up 
everybody’s act real fast”.
Of critical importance is that the journal Nature has just 
launched Nature Peer Review Trial and Database that may 
well lead to a revolution in the peer review process and would 
appear to address at least some of the concerns regarding 
transparency of the review process. Other journals should 
consider following this lead.
Are you too positive? 
What about negative data? There is a tendency for editors 
and reviewers to only accept so-called “positive data”, but 
there is also the need to publish data that, although negative, 
may still help advance the ﬁeld. How best to do that? Should 
there be a publicly accessible depository for negative studies? 
Scientists often do not dwell on their negative data, but by 
(trying) to ignore these “failures” are they also being unethi-
cal? Perhaps including a description of protocols that did not 
work together with data from those that were “successful” 
in a publication is a more honest approach—but will that 
paper be favorably reviewed and would the journal accept 
this when page restrictions apply? Whatever the approach 
we do argue that a process whereby so-called negative data 
can be made available is required.
Are changes in the peer review 
system essential? 
Evidence that bias may enter the review process, at least for 
abstract submissions, was provided by an analysis by Ross et 
al (2006) of the 67 275 abstracts submitted to the American 
Heart Association (AHA) over the 5-year period 2000–2004. 
During the period 2000 and 2001 authors names and origins 
were included in the review process; however, for 2002, 
2003, and 2004 the abstracts were reviewed anonymously 
and the data suggested that well-known laboratories may get a 
relatively free passage and that the country of origin may also   
inﬂuence acceptance. 
If bias exists in the review of scientiﬁc abstracts then al-
most certainly bias exists at the level of manuscript or grant 
review, but what can be done? Ross’s study may establish 
the viability and value of a blinded peer review process 
for the acceptance of abstracts at scientiﬁc meetings, but 
will it work for full manuscripts to journals or for grant 
applications? Some difﬁculties with the universal adoption 
of this process are, however, obvious. For instance, how 
will an author maintain anonymity and, at the same time, 
reference “previous work from our laboratory?” Another 
challenge for grant reviews will, of course, be “evaluation 
of track record”. Nonetheless, efforts do need to be made 
to reduce the suspected bias that may beneﬁt some and 
negatively impact others in the peer review of manuscripts 
and grants—based on the AHA study it is almost certain 
that author and institution bias also exists in the review 
of manuscripts and grants. Such a “halo” effect has long 
been recognized (Thorndike 1920) and certainly applies 
to many ﬁelds outside scientiﬁc publishing and research. 
Assessment of bias (Gilbert 2006) is an important task for 
the Editor/Committee Chair, but is also very time consum-
ing and how much additional work should be added to that 
already burdening most editors? 
A step towards establishing an international forum on 
such issues was made with the establishment of the Com-
mittee on Publication Ethics (COPE) in 1997. COPE has 
a current membership with editorial representation from 
346 peer-reviewed journals and the mandate to discuss 
issues related to the scientific integrity of the publication 
process. To date COPE has published seven reports (see 
http://www.publicationethics.org.uk/ and McCall Smith et 
al 2000). The establishment of COPE is certainly a step in 
the right direction, as journal editors clearly need support 
and guidance as to how best deal with suspected/alleged Vascular Health and Risk Management 2007:3(1) 42
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scientific fraud (see Jones 1999). COPE was chaired 
by the editor of the BMJ, Fiona Godlee, for the period 
2003–2005 and the BMJ, itself has been the centre of 
attention in 2005 discussing allegations concerning sci-
entific integrity against two prominent scientists—see 
below—“Publish and then perish—fraud in science and 
the case of the repeat offender.” 
“Thank you, but your (bad) review 
just cost me my job and I’m suing 
you” 
In 2000 Dr Schulze won a settlement of close to US$15 mil-
lion after the court agreed that he had indeed been victimized 
and his reputation severely damaged by a badly conducted 
peer review of his medical practice by a Health Maintenance 
Organization (HMO) (Rice 2001). Prior to the HMO’s peer 
review Dr Schulze, a general practitioner from Corpus 
Christi, Texas, held an excellent reputation of untarnished 
medical practice spanning 35 years that suffered during a 
period of investigation by his peers that lasted approximately 
6 years. The lawyer for the HMO argued that Dr Schulze’s 
victory was a set back that damaged the conﬁdentiality of the 
peer review process, which is an essential component of the 
process for maintaining the quality of health care. The fact 
is, however, that if the peer review process is unfair, if the 
rights of the individual under review are not protected, if the 
“facts” presented during the review are inaccurate, and the 
result is a damaged reputation and loss of income then why 
shouldn’t you sue? We are, of course, not recommending 
that everyone who believes that the review of their grant or 
manuscript was conducted by an incompetent or vindictive 
reviewer launch a law suit, but the case of Dr Schulze reveals 
that the process of peer review is a very serious matter and 
must be conducted fairly. The onus, of course, lies with the 
committee chairs and editors to be vigilant and recognise 
what might be considered unfair or bias in the peer review 
process, but it is up to all of us, as the reviewers, to make 
their task easier by being fair and commit the time to what is 
a very important (but usually underappreciated and unpaid) 
job. Reviews that either intentionally or simply due to lazi-
ness and/or incompetence misrepresent what the authors 
have stated also reﬂect scientiﬁc fraud or misconduct by 
the reviewer. In other professions incompetence usually 
results in penalties. Why not the same for incompetent or 
fraudulent reviewers? The solution, of course, may well be 
a few well-aimed lawsuits that will wake up the scientiﬁc 
community from its complacency; however, is that really 
what we want and would this destroy the peer review system? 
A better solution is to make the review process more open 
and accountable.
Who should peer review your 
research—the FBI or a magician? 
A strange choice, but the FBI and a professional magician 
have been used to assist the peer review process and in both 
cases, not surprisingly, the results resemble a witch-hunt. 
For Dr Mark Feldstein, formerly an investigative reporter 
with CNN and now with George Washington University 
as Director of The Journalism Oral History Project, it was 
the FBI who visited with him to discuss their interest in the   
research work that Dr Feldstein was pursuing on the late Jack 
Anderson (Feldstein 2006). Jack Anderson, who died in late 
2005, was described by Henry Kissinger as “the most dan-
gerous man in America” (others have, of course, described 
Dr. Kissinger, with at least equal justiﬁcation, in similarly 
unﬂattering terms [Hitches 2001]), but he was also the re-
cipient of the 1972 Pulitzer Prize for National Reporting and 
his career was dedicated to uncovering corruption with, as 
examples, J Edgar Hoover, Watergate, the JFK assassination, 
the Iran-Contra affair receiving his attention. It would not 
be surprising therefore if the FBI were to either recommend 
“accept only after major revisions”, or “rejection”, of any 
forthcoming publication that focuses on information obtained 
from the ﬁles of this controversial ﬁgure. 
For Dr Jacques Benveniste, discoverer of platelet acti-
vating factor (PAF) in 1970 and highly respected INSERM 
scientist, it was his decision in 1988 to pursue publication 
with colleague Dr Bernard Poitevin of data arising from an 
allergen high-dilution “memory of water” supporting the con-
cept of homeopathy that resulted in a visit from a magician 
(Davenas et al 1888; Editorial Opinion 1988). Dr Benveniste 
submitted the paper to Nature and acceptance came with the 
proviso that the then editor, Dr John Maddox, be allowed to 
send an investigative team to visit Dr Benveniste’s labora-
tory and view the studies ﬁrst hand (see Benveniste 1988a, 
1988b, 1988c; Maddox 1988 for correspondence regarding 
the review process). The make up of the investigative team, 
however, reﬂected the extreme skepticism of Dr Maddox and 
included a professional magician and a journalist intent on 
exposing fraud or, at least misinterpretation, which, arguably, 
they did (Maddox et al 1988). Not surprisingly perhaps Dr 
Benveniste’s career took a nosedive as the French scientiﬁc 
community felt that French science had been dishonoured, 
and his laboratory ultimately closed. Dr Benveniste’s honour, Vascular Health and Risk Management 2007:3(1) 43
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however, was at least partially restored with the success of 
his own company, Digibio (www.digibio.com), as well as 
a publication that seemingly supports, at least in part, the 
conclusions from his 1998 paper in Nature (Brown and 
Ennis 2001)—a view he himself maintained. “Why then 
accept a paper on 13th June to publish June 30th to destroy 
on 8th July data so easily spotted as wrong or made up?” 
(Benveniste 1988a). 
Readers will agree that neither of these examples speak 
well of the peer review process.  
Is this really a conﬂict of interest—it 
never occurred to me? 
The real challenge is whether to declare the conﬂict or to 
avoid it in real life and to avoid being on the front page of 
your hometown newspaper. One gains no credibility by 
declaring that one is the reviewer of one’s own manuscript, 
the only acceptable solution is not to review it. Similarly 
a grant review panellist should not serve on a panel where 
their own (or a grant from a colleague or collaborator) grant 
is before the panel, but, very surprisingly, this is still com-
mon practice with some granting agencies and yet is not 
recognized as a conﬂict—how can this be? No wonder there 
is scepticism about some of the decisions made in some 
countries by the funding agencies. Similar concerns can be 
raised at the university level. Can you really expect no matter 
how well structured an institution to police its own policies 
and impartially investigate questions of scientiﬁc integrity 
(see Smith 2005)?  There clearly is an urgent need for ap-
propriate policing bodies at the national or even international 
level—see section below on “Fraud and discussion of the role 
of the Ofﬁce of Research Integrity. The case for national/
international monitoring and adjudication is very strong as 
how many individual institutions have enough experience and 
expertise to adequately respond to allegations of scientiﬁc 
misconduct?” The answer is few—if any.  
Of course, conﬂicts are not only with the author and/or 
reviewer. They can also exist at the level of the editor, the 
editorial board, and the publisher.  Most recently, the editor 
of the Canadian Medical Association Journal (in 2006 ranked 
as the ﬁfth leading general medical journal in the world) was 
dismissed by the publisher, apparently for publishing articles 
dealing with marijuana and emergency contraception that did 
not accord with the views of the Canadian Medical Associa-
tion, the journal’s owner (Shuchman and Redelmeier 2006). 
Ironically enough, the editor of the journal, John Hoey, had 
previously published editorials on the similarly politically in-
ﬂuenced dismissals of George Lundberg and Jerome Kassirer 
as editors of the Journal of the American Medical Association 
and the New England Journal of Medicine respectively (Hoey 
1999; Hoey et al 1999). Bringing public attention to issues of 
“scientiﬁc integrity” may lead to the adoption of guidelines 
and the resolution of the problem. With respect to “editor 
censorship” and the Canadian Medical Association Journal 
this now seems to be the case following a recommendation 
by an independent committee established to resolve the ques-
tion of “editorial independence that the mission statement 
of the Canadian Medical Association Journal be amended 
to: “the principle of editorial integrity, independent of any 
special interests” (Birchard 2006). Decisions by the editor 
can also generate conﬂict. Thus, when Nature concluded that 
a previously published paper describing the occurrence of 
transgenic DNA in Mexican corn (Quist and Chapela 2001) 
should not have been published, “Nature has concluded that 
the evidence available is not sufﬁcient to justify the publica-
tion of the original paper” (Editorial comment 2002) issues 
were immediately raised as to the appropriateness of both 
the original peer review process and the subsequent scientiﬁc 
comments leading to Nature’s decision and as to whether the 
editorial decision was appropriate, raising the question of 
what is appropriate or inappropriate at the level of an editor’s 
decision concerning the submission/review of a manuscript 
(see also the reference to Dr Jacques Benveniste—a case that 
we have already discussed. 
Furthermore, the decision fueled the ongoing debate 
about the role of agricultural biotechnology companies and 
their relationship to the University of California and to the 
original decision by the university not to grant tenure to Ig-
nacio Chapela. Science loses its intrinsic claims to truth and 
objectivity with events like this. More recently, the editor 
of Cell, Emilie Marcus, retracted a widely noted paper from 
Brazilian scientists that had claimed that the parasite respon-
sible for Chagas disease inserted DNA into the host genome 
(Nitz et al 2004), on the basis that following, “careful and 
extensive review by independent experts…do not provide 
strong support for the central hypothesis and are open to   
alternative interpretations” (Retraction 2005). The paper 
now appears online marked with the word “RETRACTED” 
in red. Both of these decisions by editors raise important 
questions about the peer review process, and how the papers 
originally passed muster; in the absence of fraud would it 
not be better to simply let the scientiﬁc debate play out in 
print or online.  After all, as Richard Feynman famously 
noted, uncertainty is a key feature of scientiﬁc discovery 
(Feynman 1988). Vascular Health and Risk Management 2007:3(1) 44
Triggle and Triggle
Conﬂicts in the peer review process can also be political 
or religious, derived from some vested interest or ideology 
whose interests are threatened. The decision by the US 
Food and Drug Administration (FDA) not to approve over 
the-counter availability of a post-coital contraceptive pill 
(“Plan B”) despite the approval by its scientiﬁc advisory 
board, a decision that the Government Accountability Ofﬁce 
(GAO) itself described as “unusual” (Government Account-
ability Ofﬁce 2006) is certainly linked to the present Bush 
administration support for and by the powerful “right-to-
life” community (Drazen et al 2004; Davidoff 2006). Not 
coincidentally, the FDA announced a possible resolution 
of the issue on the very day that the nominee for the FDA 
Directorships, Andrew von Eschenbach, was to appear before 
Congress at a conﬁrmation hearing (Saul 2006). More recent-
ly, a paper published in Science by an Oregon State University 
student, Daniell Donato, arguing that salvage logging post-forest 
ﬁre might be detrimental rather than beneﬁcial (Donato et al 
2006), was challenged prior to publication by faculty members 
from that institution, reportedly on the basis that its publication 
would offend the logging industry in Oregon (Brainard 2006).   
Fortunately for both the causes of integrity and peer review the 
editor of Science declined to delay publication (Kennedy 2006). 
In addition, to the credit of Oregon State University (OSU), the 
Provost and the Chair of the Faculty Senate of OSU came out 
with a strong statement defending academic freedom. Conﬂicts 
in the peer review process also occur through the vested inter-
ests of governments. The American Association of Petroleum 
Geologists rejected two papers for publication post acceptance 
for publication because of a US Government policy prohibiting 
publication from countries under trade embargo. In these cases 
one of the authors worked for the National Iranian Oil Company 
and in the other the paper’s authors in Norway had obtained 
data from the oil company (Guterman 2006; Gripsrud 2006). 
Both articles will be published elsewhere so you have to won-
der what has been accomplished by this attempt at censorship, 
a phenomenon that appears to be on the rise in an increasingly 
xenophobic United States. 
Finally, conﬂicts appear between the authors, the journal 
and the funding source. These typically appear when the 
funding source (almost without exception of commercial 
origin) wants to delay or even prohibit publication altogether, 
in the latter case typically because the published paper would 
not be favorable. Such cases have been discussed extensively 
elsewhere (Krimsky 2003; Shuchman 2005; Triggle 2005a) 
and are less a reﬂection of the peer review process than of 
the failure to eliminate the conﬂicts of interest before the 
research is initiated. 
Having a problem publishing your 
paper? No worries—just launch 
your own journal! 
Of course, you will need a wealthy backer and, if you 
accept the views put forward in an article in The Lancet 
(Garne et al 2005), the tobacco industry may have pro-
vided backing and undue influence in establishing the 
research journal Indoor and Built Environment. Garne 
et al (2005) report that, since its birth in 1987, Indoor 
and Built Environment has published a surprisingly large 
percentage of manuscripts from authors having tobacco 
industry connections that reflected a favorable view on 
the health effects of environmental tobacco smoke. Such 
revelations only add fuel to the fires that are flaring up 
globally concerning scientific integrity and what really 
is “good science”. According to many, good science is 
that published in journals that have a high impact, but is 
this true or just another urban legend reflecting unsub-
stantiated beliefs maintained for self-perpetuation of the 
scientific elite?
Publish or perish or publish and then 
perish?—The real meaning of JIF 
The emergence of the journal impact factor or JIF has greatly 
inﬂuenced how we evaluate science. The argument in favor 
of “impact factors” was ﬁrst mentioned some 50 years ago 
(Garﬁeld 1955) and its history and meaning reviewed recently 
(Garﬁeld 1999, 2006). Thus, JIF was originally proposed as 
a measure for selection and inclusion of a journal in Science 
Citation Index (Garﬁeld 1999, 2006), but has become exten-
sively used as a means of deﬁning the impact of a scientist’s 
research and, indeed, an individual’s career and the Institute 
of Scientific Information’s (ISI) Journal Impact Factor 
has served as the cornerstone for categorizing journals for   
approaching 50 years. The number of citations for an   
article in a given year, the numerator, and the denominator 
determines the JIF, which is the number of articles/reviews 
published in the same journal during the past two years. Most 
evaluators misunderstand the true meaning of JIF and incor-
rectly assume/infer that a publication in a journal with a high 
JIF must have a high impact. This is far from the truth as we 
will indicate. This confusion is, perhaps, not surprising as, 
according to the science ﬁction novel, Hitchhikers Guide to 
The Universe, by Douglas Adams, the second greatest com-
puter of all time, “Deep Thought” took 7.5 million years to 
determine that 42 was the ultimate answer, but what was the 
ultimate question? Similarly, to provide a numerical value Vascular Health and Risk Management 2007:3(1) 45
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to the ‘impact’ of a scientist’s publications is of question-
able signiﬁcance. What does it really mean when a reviewer 
states: “Dr X publishes in high impact journals?” Does this 
really imply that Dr X’s publications also have a high impact? 
Careers for scientists are made or lost based on an individual’s 
track record—publish frequently and in high impact journals or 
suffer the consequences. Is this fair? The argument in favor of 
such a draconian approach to career selection and progression 
is, of course, Darwinian. During the past 40 years there has 
been an increasing attention paid to where your paper is pub-
lished and, of course, we all believe, or, at least, hope that our 
data are worthy of a paper in high impact (JIF) journals such as 
Nature or Science. The beneﬁt to the authors of publishing in a 
high proﬁle journal is the anticipation that their article will have 
greater visibility and, therefore, more likely to be cited. Such 
beneﬁt also contributes to the pressure to obtain results and 
to publish, a pressure that is not necessarily always beneﬁcial 
to science or to the scientist. This issue is well presented in a 
recent novel, “Intuition” (Goodman 2006), set in an active and 
competitive research laboratory in the Boston area. 
So what is the answer? Generally it is the subscriptions to 
the higher impact journals that libraries will purchase and it 
is this same group of journals that specialists are most likely 
to peruse. But the “80:20” phenomenon indicates that 20% of 
publications accounts for 80% of the citations (see Garﬁeld 
2006). Whither the others? It has been stated that during the 
period 1900–2005, 38 million articles were published, but 
only 0.5% of these have been cited more than 200 times 
and half were not cited at all (Garﬁeld 2006). One can only 
speculate as to why the authors of these 19 million uncited 
papers did not consider citing these papers in subsequent 
publications. 19 million peer-reviewed papers that have 
never been cited—does this imply that this immense amount 
of research effort was all in vain? Does a paper with zero 
citations after, say, 5 years imply that this publication had 
zero impact on the research ﬁeld and that this research was 
entirely devoid of impact? Whatever your views it should 
be apparent that, to coin a popular phrase, “the proof is in 
the pudding”. In other words it is essential to evaluate the 
impact of the individual paper and take into account not only 
where it was published but, in particular, also how well it 
has been cited and by whom (a process that can be readily 
accomplished by access to ISI Web of Science)—a paper 
in a high impact journal does not necessarily equate with a 
high impact paper, it is the citation frequency that is more 
important. As stated by Seglen (1997): “Article citation rates 
determine the journal impact factor, not vice versa,” and “JIF 
correlates poorly with actual citations of individual authors.” 
The views of Seglen have also been referenced by Garﬁeld 
(2001). Despite these serious concerns about the misuse of 
JIFs it is still common practice for reviewers to refer only 
to the JIF and not consider the content and impact of the 
individual paper although, of course, it may be argued that 
for a recently published article insufﬁcient time has elapsed 
to determine an impact. Other considerations to bear in mind 
when using the JIF is the problem of padding the citation 
frequency by self-citations—a process facilitated by jour-
nals that have the advantage of a rapid-review and e-pub 
process and exacerbated by multi-authored papers wherein, 
each individual author may cite the paper in a subsequent 
publication—perhaps leading to several citations of the one 
piece of work in one year by the same group of authors! So, 
when it comes to the funding of research where should the 
money go? Should it go an individual, or group of individu-
als, that publishes solely in high impact journals, but with 
limited (perhaps self) citations, or should it go to a project 
from scientists publishing in less prestigious journals but 
with frequent citations by their peers? Purists might argue 
that the number of citations is irrelevant and that publishing 
in the “best” journals is the chief criteria for funding, but then 
what is the meaning and relevance of “impact”? A potentially 
more useful index of individual productivity, “h”, has been 
proposed by Hirsch (2005) where h is deﬁned as the num-
ber of papers with citation number >h. With the increasing 
impact of web-based publications alternatives to the ISI JIF 
ratings should also be considered. Bollen et al (2005) have 
also argued that, in part because of the emerging impact of 
web-based publications that are not included in ISI’s selected 
list (a point also raised by others), the JIF does not provide 
an accurate assessment of the true impact of the published 
article. These considerations thus necessitate that we should 
look at other means of assessment, such as web hits and 
downloads that can provide additional data to that obtained 
via JIF and associated citations for assessing impact. 
In conclusion, if you must use JIF then ﬁrst you must 
understand what it really means and then use it appropri-
ately and fairly and also seek other parameters to assess the 
impact of the author(s) research as well as the paper/grant 
that is being assessed. 
Fraud in science and the case of the 
repeat offender 
The difﬁculty with allegations of scientiﬁc fraud is the 
need to determine with complete certainty that malicious 
intent and not interpretation error, or simply bad laboratory   
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has been discovered, has often been explained as reﬂecting 
the misdirected activities of an individual suffering from 
excessive stress—perhaps a post-doctoral fellow who is anx-
ious to ensure a successful career progression. Furthermore, 
some well-known instances of fraud are often referred to as 
hoaxes thus suggesting that the intention behind the offence 
was simply that of an innocent prank. A famous case is the 
Piltdown forgery—in 1913 a skull was discovered at the 
Piltdown archaeological site in England that seemingly had 
similarities to a human cranium and an ape’s jaw thus ﬁtting 
the expectation of the day that brain size increased ﬁrst in 
the evolution from ape to modern man and was the driving 
force for this change. Additionally, the discovery probably 
ﬁtted also into the political-social climate of the time—given 
the then still signiﬁcant power and inﬂuence of the British 
Empire: what more natural that this “dawn man” should be 
British? However, in 1953 the ﬁnd was exposed as a “hoax” 
and the skull revealed to be made up from the cranium case 
of a modern man and the jaw of an Orang Utan. Specula-
tion, however, still remains as to whom was responsible 
although it has been argued that the perpetrator was Martin 
Hinton, the curator of Zoology at the London Natural His-
tory Museum (Gee 1996). Possibly the Piltdown hoax was 
originally fabricated as a joke, but the truth took 40 years to 
emerge and confused both the literature on the evolution of 
hominids as well as many physical anthropologists (Walsh 
1996). Another notable and more recent case is that of Dr 
William Summerlin who, in the early 1970s, was a scientist 
working on organ transplants at the Sloan-Kettering Insti-
tute for Cancer Research. Dr Summerlin was discovered to 
have used a black felt-tip pen to enhance evidence for the 
success of grafts of black skin grafts from black onto white 
mice. Investigations revealed that earlier data concerning the 
success of human cornea transplants into rabbits was also 
suspect. Using a black felt-tip pen to falsify data would be 
considered rather amateurish today given the potential for the 
use of computer-assisted manipulation. Unfortunately there 
are many other cases of scientiﬁc fraud indicating that the 
problem is more common than should be expected (see Lock 
et al 2004). However, it must be admitted that it is, in most 
cases, impossible for the journal to detect scientiﬁc fraud.
It may be argued that scientiﬁc fraud set in the framework 
of a particular political ideology is a particularly dangerous 
event. An obvious example is that of Troﬁm Lysenko whose 
inﬂuence on Soviet agriculture was supported by Joseph Sta-
lin and contributed signiﬁcantly to the massive starvation in 
the Soviet Union in the 1930s (Graham 1993).  Today, and 
paradoxically enough in the United States, we see a consider-
able inﬂuence of political and religious ideologies on science 
policy driven enthusiastically by the Bush administration 
(Mooney 2005; Triggle 2005b). Two recent examples of such 
conﬂicts were discussed in a previous section (“Is this really 
a conﬂict of interest it never occurred to me?”)
Rather than simply viewing scientiﬁc fraud as the isolated 
lapse of an otherwise honest scientist, as was the argument with 
Dr Summerlin and, initially, with Dr John Darsee, the current 
view is that many cases of scientiﬁc fraud really reﬂect repeat 
offenders. As an example, Dr Darsee, a young cardiologist and 
NIH fellow, was discovered falsifying data while at Harvard 
in 1981. It was ultimately revealed that he had been falsifying 
data for many years at several (at least three) institutions and 
the NIH, through the NHLBI, launched an investigation (see 
Culliton 1983). The Darsee case led to revealing questions 
concerning the role and responsibilities of the co-authors of 
Darsee’s published papers, but, as it happens, the co-authors 
were unaware of any falsiﬁcation with the argument, perhaps, 
being that Darsee’s “success” may have clouded their judg-
ment that, after all, (initially) reﬂected well on his mentors and 
the institutions. Questions were also raised about the level of 
supervision by Dr Darsee’s mentors. Of particular interest and 
concern was that a report on the “Darsee affair” (Stewart and 
Feder 1987) may itself have been ﬂawed (Braunwald 1987). 
This case thus also stresses the importance of a fair peer review 
process to investigate the extent of the alleged fraud (Nature 
opinion article 1987). Concerns on the pressures placed on 
postdocs to boost their publication record to obtain fellowship 
support or their ﬁrst faculty position and/or research grant are 
a major concern (Benderly 2006).
Scientiﬁc fraud is now beginning to be seen as no differ-
ent from any other criminal and often perpetrated by a repeat 
offender. A US-based survey suggests that the incidence of 
falsiﬁcation, fabrication and plagiarism is higher than one 
would have hoped with approximately 33% of the partici-
pants admitting to one or more of the top 10 (mis) behaviours 
(Martinson et al 2005). So where should behaviour modiﬁ-
cation begin? Presumably such modiﬁcation should start at 
the top with national governments and academic institutions 
establishing policies that are both followed and enforced. 
Indeed, fraud in science, whether initially intended as 
hoaxes or planned with career and proﬁt-making intentions, 
not only ruins the careers of the perpetrator, but also, po-
tentially, their innocent colleagues, as well as tarnishing the 
reputation of the institution where the work was performed 
and reducing the conﬁdence of the public in the value of 
scientiﬁc research. Fraud in health research may also have 
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lives; fraud in other areas of science may, of course, affect 
the economy and the lives of people. It can been argued that 
one approach to dealing with scientiﬁc fraud is to proceed 
through civil courts as, likely, misuse of grant funds is also 
involved (see Smith 2005). 
Several recent instances of alleged fraud in nutrition 
research—Drs Ram B Singh of India and RK Chandra from 
Canada (see White 2005; Smith 2005, respectively), in cancer 
research with Dr Jon Sudbø of Norway, and, in the area of 
stem cell research, Dr Woo Suk Hwang of South Korea have 
been reported. Interestingly, all of these scientists achieved 
almost hero status in their own countries: achieving such 
status may be a signiﬁcant motivation for scientiﬁc fraud. 
An analogy is the athlete who receives the gold medal at 
the Olympics but then has it stripped from them (and their 
country) as the result of a drug-tainted urine sample. In the 
case of Dr Hwang the rise and fall were both dramatic and 
fast with his landmark paper on stem cells from a cloned   
human blastocyst (embryo) ﬁrst published in Science in 
March 2004, a second paper in Science in June 2005 and both 
withdrawn in an editorial retraction in January, 2006 (Hwang 
et al 2004, 2005; Kennedy 2006). The only good news in this 
the Hwang case is that his Afghan cloned puppy, “Snuppy”, 
was, apparently, real (Lee et al 2005; Lee and Park 2006). 
The negative fall-out for stem cell research internationally has 
affected not only Dr Hwang’s US-Based collaborators but, 
by creating public and scientiﬁc anger and dismay, will likely 
signiﬁcantly slow progress in this entire ﬁeld. The impact of 
the other allegations noted above in terms of nutrition and 
human health are, potentially, no less severe. The reaction 
of the Norwegian government to the fraudulent study by Dr 
Sudbø (Morris 2006) has been strong, and may lead to the 
government passing legislation that will make medical fraud 
a criminal offence that probably should be extended to all 
areas of science. 
Who should investigate allegations of scientiﬁc miscon-
duct? Arguably journal editors may be the ﬁrst to become 
informed of such allegations, but is it their responsibility to 
pursue or the institution(s) where the research was pursued? 
We have argued already that certain responses from edito-
rial ofﬁces may be inappropriate (re The Benveniste case) 
so perhaps it is best that the institution(s) where the research 
was conducted should ﬁrst investigate the allegation(s). This 
appears to make sense, but, in the case of Dr Chandra, proved 
difﬁcult. Furthermore, with scientiﬁc research frequently 
involving multiple centres and more than one country the 
argument for an international authority to deal with issues 
of scientiﬁc integrity is strengthened (see also White 2005; 
Smith 2005). However, institutions and journals should 
perhaps be the repositories for the electronic data submit-
ted together with manuscripts for publication purposes? 
Adopting such a system would not prevent publication but 
would provide a fall-back check system. There are national 
requirements for maintaining research records (in the United 
States 3 years from the termination of the grant and 2–4 
years from the termination of the contract. In Canada a 7-
year period is required. In Australia the recommendations 
are 5 years from the date of publication, but in some areas, 
such as for clinical trials a minimum of 15 years is recom-
mended). An external data repository would eliminate the 
potential for those accused of data fraud of arguing that the 
records were lost (apparently eaten by termites in the case 
of Dr Singh—see White 2005). Data repositories should 
not hold up or prevent publication but would provide a 
fall-back check system. Such data repositories exist, of 
course, for the storage of X-ray crystallographic data and 
nucleic acid and amino acid sequences and almost without 
exception deposition of these data is a prerequisite for 
journal publication. 
The Ofﬁce of Research Integrity, or ORI, evolved from 
the Ofﬁce of Scientiﬁc Integrity that was established in 
1989 in response to an increasing number of allegations of 
scientiﬁc misconduct in the areas of biomedical and behav-
ioural research in the USA. The ORI, ofﬁcially launched in 
1993 and independent from the NIH, has as its mandate the 
promotion of scientiﬁc integrity at the international level 
and holds conferences and issues reports (see http://ori.
dhhs.gov/). The ORI is located in and supported by the 
Ofﬁce of Public Health and Sciences in the Department of 
Health and Human Services in Rockville, Maryland, USA.   
A panel to oversee research integrity in biomedical research 
has been formed in the United Kingdom. A recent paper by 
a member of the ORI (Pascal, 2006) outlines some of the 
issues that the ORI faces in investigating allegations and, 
of particular interest, are the rights of the complainant, the 
accused and the interests of the institution. The potential 
of retaliation against the complainant is a major issue that 
may well prevent more cases of fraud being uncovered and 
clearly needs attention.
The UK Panel for Research Integrity in Health and Bio-
medical Sciences was launched on April 12, 2007: some 
concern as to its independence has been justiﬁably expressed 
since the panel will accept money from the pharmaceutical 
industry (Giles 2005). Regardless of issues of independence 
we argue that the establishment of national ofﬁces for the   
investigation of questions of scientific integrity is an Vascular Health and Risk Management 2007:3(1) 48
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important step forward as part of an international approach 
to dealing with this criminal activity.
An indication that scientiﬁc fraud is being taken more 
seriously is the case of Dr Eric Poehlman of Vermont and his 
sentencing by the federal government for falsifying data for 
17 grant applications (see “Focus on Fraud”, Nature Medi-
cine, May, 2006). The prosecution of Dr Poehlman resulted 
from the combined efforts of the US Attorney’s Ofﬁce for the 
District of Vermont, the ORI and the Ofﬁce of the Inspector 
General and provides an example for other jurisdictions and 
countries to follow (see Dahlberg and Mahler 2006; Pascal 
2006; Sox and Rennie 2006).
Plagiarize 
Deﬁned in the Concise Oxford Dictionary as: “1. take and 
use (the thoughts, writings, inventions, etc. of another per-
son) as one’s own. 2. pass off the thoughts etc. of (another 
person) as one’s own.” This constitutes intellectual theft 
and documentation of its occurrence in academia can be 
traced back at least 200 years with a clear case of plagiarism 
reported by Dr Baumes and concerning a thesis submitted 
by a Francois Bidault to the University of Paris in 1804. 
Plagiarism today is apparently rampant at the level of high 
school and university students: according to Donald McCabe 
Founder and President of the Center for Academic Integrity 
(www.academicintegrity.org), on most campuses 70% of 
students admit to some cheating (Campbell 2006). Warn-
ings to students about plagiarism receive high visibility in 
academic institutions, but how seriously are such policies 
policed? Universities may be reluctant to proceed to formal 
dismissal when high student quotas are required to maintain 
government grants and/or tuition revenue. 
Plagiarism is likely also a problem with academic 
publication, although precise data are not readily available 
(Martinson et al 2005; Nature special report 2005). Indeed, 
the impact of plagiarism was put to song by Tom Lehrer 
(a satirist of the 1950s and mathematician and former Har-
vard student and teacher) about the Russian mathematician 
Nicolai Ivanovich Lobachevsky (the name apparently cho-
sen for rhyming purposes and not necessarily to imply that 
Lobachevsky was guilty of plagiarism!):  
“Plagiarize,
Let no one else’s work evade your eyes,
Remember why the good Lord made your eyes,
So don’t shade your eyes,
But plagiarize, plagiarize, plagiarize...
Only be sure always to call it please ‘research’.”
Although the dictionary deﬁnitions of plagiarism are 
clear enough, in practice their application is more difﬁcult. 
All of us recognize the “bloody obvious” cases where a 
Shakespeare sonnet turns up in a high school poetry contest 
and certainly “cut-and-paste” and Internet search engines 
have facilitated such plagiarism. However, plagiarism 
software now makes this type of event much easier to 
detect. More difﬁcult for science publishing is the reuse of 
descriptions of experimental methods; many experimental 
methods are essentially boilerplate and there are, after all, 
only so many ways to say that, “A was mixed with B to 
form C which was used in the next reaction”. Referenc-
ing the original source of the ‘methodology’ should, of 
course, be expected. Also difﬁcult is “self-plagiarism” 
where portions of the author’s own work may be reused in 
a subsequent publication: how does one deal with the (fairly 
typical) process of incremental publication where work may 
appear as a meeting abstract, a brief or preliminary com-
munication, a full paper and perhaps a ﬁnal book chapter 
or review article, or even a second ‘review’ article that is 
minimally different from the original?  At what stage of 
self-plagiarism should this be termed fraud, or is it fraud? 
The answer is clearly full and clear disclosure of the nature 
of the preceding publication(s) (and awareness of the nature 
of copyright law) and how the new publication derives from 
and expands on the original.
Plagiarism is, of course, not conﬁned to the word of 
scientiﬁc publication.  Kaavya Viswanathan, the Harvard 
student and currently celebrated author of the “chick-lit” 
novel, How Ophal Mehta got Kissed, got Wild, and got a 
Life, acknowledges that portions of the text were similar to 
work from another author (Smith 2006). And Vladimir Putin, 
President of Russia, was accused of incorporating into his 
PhD dissertation material from a previously published book 
by University of Pittsburgh professors David Cleland and 
William King (Allen-Mills 2006; Gaddy 2006). 
For playwrights, artists and poets, at least in the past, it 
may have been considered acceptable to “improve” upon 
the works of their predecessors, but that is unlikely to pass 
without judgement today. But what about the authors of text 
books? As Richard Posner (2007) points out in his Little Book 
of Plagiarism, parts of  T.S. Eliot’s widely acknowledged 
masterpiece The Waste Land (1922) are really “a tissue of 
quotations (without quotations marks).” Eliot seemingly ac-
knowledges his and other’s faults when he states: “Immature 
poets imitate; mature poets steal; bad poets deface what they 
take, and good poets make it into something better, or at least 
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“Honestly, it wasn’t plagiarism—I 
had a dream”
We have all heard stories of plagiarism that have been 
vigorously denied by those accused, but do they have a 
genuine defence? Is there evidence for true “unintentional 
plagiarism”? Is it possible that the culprit has absorbed some 
fact or idea and honestly believed it was their invention? 
Cryptomnesia, or unconscious plagiarism, has been reported 
in several studies (see Brown and Murphy 1989; Marsh and 
Boyer 1993) thus providing credence to this potential defence 
against charges of scientiﬁc misconduct. According to Brown 
and Murphy prominent ﬁgures from Freud, Keller, and   
Nietzsche have all been accused of this version of plagiarism. 
And Kaavya Viswanathan also advanced this argument in 
defence of her plagiarism. The frequency of genuine cases of 
cryptomnesia remains unknown, but it is unlikely that it is at 
the pandemic levels that are needed to explain the reported 
high incidence amongst students.
What a good idea! 
Less readily substantiated is the theft of ideas from grant 
applications and abuse of the peer review process so that the 
reviewer can beneﬁt from the ideas of others whose grants 
the reviewer has just torpedoed. The US Ofﬁce of Research 
Integrity has also taken this problem under its wing and 
it will be interesting to see the extent of the problem that 
emerges from their investigations (Ready 2006). Is legal 
recourse the approach? We would need to know who to sue 
when mistakes in the peer review process are made. Is it the 
deceitful reviewer, the committee chair or the funding orga-
nization? There can be quite subtle ways by which reviewers 
dismiss the work of others and, at the same time, promote 
the work that their team/institute is pursuing. Is this ethical? 
An example of unethical behaviour is promoting the use of 
stem cell technology for tissue repair over other approaches 
simply because stem cell technology is new and current and 
in vogue and a technique being used by the reviewer! We 
use this example NOT as an argument against stem cell tech-
nology as a promising area for research (which it clearly is), 
but rather an indication of a manipulative reviewer abusing 
the peer review process in order to promote their personal 
goals. Another frequently and often inappropriately used 
term to dismiss a grant is “descriptive”. Descriptive infers 
that the research is not “mechanism driven” and therefore 
will not provide the answer to the question being addressed. 
But what was the question being asked and has the reviewer 
really considered the hypothesis being tested? Research 
is progressive and with each advance it is anticipated that 
another piece of the overall puzzle is found and placed into 
the picture. If one takes the “reductionist” viewpoint then 
one needs to take this to the gene level, but then are not we 
missing what are happening at the organ, whole organism, 
and community level? 
Academics and business—a 
marriage made in Heaven or in Hell? 
There has, particularly during the past 10–20 years, been 
an increasing interest in promoting the business side of 
academic science with governments and universities help-
ing to facilitate the licensing of intellectual property (IP) as 
well as the evolution of spin-off biotechnology companies. 
Indeed, there have been a number of spectacular successes, 
for instance, Chiron Corporation that was founded in 1981 
by Professors Rutter, Penhoet, and Valenzuela: all three 
founders were professors of biochemistry in California   
(Dr Rutter was Chairman of the Department of Biochemistry 
and Biophysics, UCSF). The beneﬁts of successfully spawn-
ing spin-off companies are multiple and, in particular, results 
in the creation of jobs for graduates as well as revenue for 
the inventors, for the institutions, as well as, by promoting   
employment and GDP, generating taxes for governments. 
There is also a societal impact in so far as it can be argued 
that such companies provide the impetus that facilitates the 
translation of a discovery to a beneﬁcial product—be it a 
therapeutic, a device, or a new technology. Similarly licens-
ing of IP can, in fact more rapidly than spin-offs, generate 
wealth. 
But are licensing and the generation of spin-offs all roses? 
To start with, without doubt, there have been many more 
failures than successes when it comes to spin-offs. Secondly, 
most universities do not really have the in-house expertise 
to advice, nurture and manage the business interests of aca-
demics and to develop such expertise could prove to be an 
unproﬁtable drain on their budgets. Thirdly, most academics 
have minimal business aptitude and, furthermore, should 
they be developing and/or managing companies when they 
are employed as full-time academics? Fourthly, who really 
owns the IP? Universities have many, sometimes overly 
complex, models of IP ownership, but which model is best? 
This is often an emotional issue and, in many instances, the 
academics may also contribute personal funds to protect the 
IP. Fifthly, the situation of IP can become very tricky when 
trainees are involved, notably graduate students, and univer-
sity administrators are advised to avoid this quagmire. For Vascular Health and Risk Management 2007:3(1) 50
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instance, who really “owns” the IP when it was “discovered” 
as part of a student’s thesis project? What recourse is there 
if part of a student’s thesis or publication is used as part of a 
patent application or license agreement without their knowl-
edge or agreement? No doubt these problems arise, but how 
are they dealt with and, indeed, are they dealt with or just 
hushed up? Indeed, we suspect that many universities are 
ill equipped to handle such matters in a fair and transparent 
manner. Universities rarely take the high road and make the 
righteous decision in such investigations, partly in the hope 
of avoiding adverse publicity or fear of reprisal or litigation 
from the guilty party. Such decisions make it difﬁcult for 
the whistle-blowers who themselves may feel threatened. 
Certainly, students should never be ‘employed’ to pursue 
a project when the question of IP and conﬁdentiality is 
likely to impinge upon the advancement and goals of their 
academic program. 
In any event, most universities do not make money from 
sale of their IP and some have argued that universities are, 
by over enthusiastically pursuing commercial objectives, 
losing sight of their principal objective, namely contribut-
ing to and maintaining the intellectual commons (inter 
alia Krimsky 2003; Leaf 2005; Triggle 2005a; Boettinger 
and Bennett 2006). Ultimately, universities may even lose 
their special role and be treated as just another commercial   
enterprise subject to the rules of the business marketplace. In 
Madey vs. Duke the Court of Appeals for the Federal Circuit 
disallowed a defence that the experimental (research) use of 
patented material without a license or royalty payments was ap-
propriate in a university setting. The court revealed in the decision 
that, “..... Duke ... like other research institutions .....  is not shy in 
pursuing an aggressive patent licensing program from which it 
derives a not insubstantial revenue stream” (Eisenberg 2003; 
Madey vs Duke University 2002). After all when most universi-
ties are established from public funds they then have a competi-
tive advantage over truly commercial companies.
Academic-industrial conflicts also arise when the   
industrial partner attempts to dictate the contents of, or even 
suppress, all or portions of a scientiﬁc paper (Triggle 2005a). 
The Journal of Occupational and Environmental Medicine 
has announced that it will retract a paper that it published 
in 1997 that claimed no association between cancer and 
hexavalent chromium (Zhang and Li 1997). This conclusion 
contradicted a previous paper by the same authors and in what 
the Wall Street Journal described as “a black eye for scien-
tiﬁc publishing” it appears that the 1997 paper was “actually 
conceived, drafted and edited by consultants for the PG & E 
corporation” that was at the time involved in litigation over 
this very issue (Waldman 2005, 2006). Similarly, the New 
York Times has reported that articles published in journals 
that advocate one drug over another may actually reﬂect little 
more than a commercial message rather than a balanced and 
objective analysis (Carlat 2006). Thus, in a paper entitled 
“A review of the evidence for the efﬁcacy and safety of 
trazodone in insomnia” (Mendelson 2005) it is noted that 
“Sepracor Inc assisted in the preparation of this manuscript 
and Dr Mendelson received compensation from Sepracor in 
support of the development of this manuscript”. The paper 
concluded with a cautionary comment about the safety of 
trazodone’s use, but what is not noted is that Sepracor is the 
manufacturer of Lunesta™ a non-generic insomniac agent 
that both competes with trazodone and is more expensive. 
Regardless of the validity of Mendelson’s conclusions these 
conﬂicts should be unacceptable in scientiﬁc publishing.
So, where are we? 
First of all we do not wish to leave the reader with the   
impression that the peer review system is obscenely corrupt, 
that plagiarism is rife, that scientists are, by nature, atten-
tion-seeking frauds intent on being media stars and making 
a quick dollar—although some scientists have one or more 
or even all of these characteristics. Scientists are no differ-
ent from any other groups in society and, like many other 
analogous comparisons, a few rotten apples will always be 
found. What scientists must ensure is that the public does 
not come to believe that is not just the apples but that the 
barrel itself is rotten. Indeed, when it comes to detecting 
fraud, new technologies should enable us to be much more 
analytical when it comes to peer review and issues of integrity 
and frauds are exposed, thus the process is evolving and the 
purpose of this review is, we hope, to speed up the evolution-
ary process—some may call this intelligent intervention. We 
also stress that we are certainly not the only scientists to 
argue for reform in the peer review system as well as the 
monitoring of science in general and the concerns that 
we have raised are shared by others whose contributions 
to this subject could not all be acknowledged in our brief 
overview (see also Horrobin 2001). What should now be 
apparent to the reader is that scientists, like other groups 
within society, consist of a majority of honest citizens 
together with a minority of less scrupulous individuals 
who, to varying degrees, will manipulate the system for 
their own benefit. Should this surprise us? The answer is 
“no”, but what needs to be changed is how such ‘manipu-
lators’ are dealt with by society. We have already argued 
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be pursued by the institution(s) where the alleged fraud 
was committed but should be referred to, as appropriate, 
national or international agencies (such as the equivalent 
of the ORI). Scientific fraud, in its many manifestations, 
is no different from any other form of fraud and should be 
dealt with as such with appropriate penalties. Accepting 
this philosophy will be a major step forward for science 
and for public confidence.
What should we do? 
We can offer recommendations, but, given the potential that 
the publication of fraudulent data not only severely damages 
the credibility of scientiﬁc research but also affects the health 
of the population we believe that changes are urgently required. 
Furthermore, although we recognise that peer review depends on 
the good will and commitment of the reviewers, the peer review 
system needs to evolve into a process that is truly accountable 
and devoid of bias with any attempts by reviewers to sabotage, 
either through intent, dishonesty or incompetence, acted upon 
by appropriate, possibly legal, action. These changes require 
cooperation by both academic (and other) institutions and na-
tional and international bodies that have the power to investigate   
allegations of corruption. 
Thus, we prefer to make just a limited number of spe-
ciﬁc recommendations that may set the stage for further   
discussion:
1.  The establishment of the equivalent of the Ofﬁce of 
Research Integrity (ORI) in other countries would be a   
major step forward for the recognition that scientiﬁc fraud 
is a serious and, potentially criminal matter. As already 
noted comparable ofﬁces have been established elsewhere 
(UK) and/or legislation is being considered (Norway).
2.  Appropriate safeguards designed to protect both the 
whistleblower and the accused.
3.  Processes whereby the apparent bias in peer review can be 
reduced are urgently required and should be evaluated. At 
the level of journal publications the “open” review process 
adopted by the journal Nature may be one such process 
and another potentially beneﬁcial process would be the 
publication of “signed” précis of the reviews together with 
the published article. Transparency and accountability 
should always be prominent in peer review.
4.  Heightened awareness and education at all levels con-
cerning the seriousness of scientiﬁc fraud in all of its 
manifestations.
Scientists are not, of course, the only guilty people, and 
certainly not the guiltiest people.  There is scarcely a day 
without a newspaper or television headline about some new 
criminal ﬁnancial activity, where some public ﬁgure is not 
taking a “perp walk”, where some new abuse of human rights 
has not occurred, where a politician is found with a hand in 
the cookie jar or in bed with a secretary, or where the car sold 
to you as just driven by one old lady to go back and forth to 
church actually has 200 000 miles on the odometer and has 
been in three major wrecks. But we are not surprised by these 
events; indeed we almost anticipate them since public expec-
tations of the ethics and honesty of businessmen, politicians 
and used car salesmen are not high. But the public expectation 
of science is much higher and thus the fall from grace is more 
signiﬁcant and ultimately far more damaging. 
The words of Francis Bacon (1561–1626) should be our 
guide:
“For myself, I found that I was ﬁtted for nothing so well 
as for the study of Truth .... and as being a man that neither 
affects what is new nor admires what is old and that hates 
every kind of imposture.”
Other issues related to the safety of clinical trials and 
human testing have recently hit the headlines (Caplan 2006) 
and with globalization also being applied to clinical trials   
inevitably questions of ethical standards have arisen and 
stress the need for an international monitoring and, most 
likely, tightening of these standards (Jayaraman 2004; Nundy 
and Gulhati 2005). There is certainly the need for close scru-
tiny in this arena. The life-threatening problems that arose in 
March 2006 as a result of the phase 1 trial with TeGeniro’s 
“superagonist”, TGN 1412, of the immune system may lead 
to changes in the regulatory processes for the testing of new 
biologic drugs in humans (Sheridan 2006). 
Finally, the truth is, of course, a sometime thing. The 
decision by Allen Dulles, then the Director of the Central 
Intelligence Agency, to place the words, “For ye shall know 
the truth and the truth shall make you free”, at the entrance to 
the CIA building seems now seems in light of past and ongo-
ing events by the CIA to be a major irony.  Science needs to 
hold to the original standards of John 8:32, and leave relative 
truth to the politicians, for that is their expertise.  
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